E3 ubiquitin-protein ligase CBL-B, 632-, Casitas B-lineage lymphoma proto-oncogene b, RING finger protein 56, SH3-binding protein CBL-B, Signal transduction protein CBL-B, CBLB, RNF56
E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. It also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. It may also be involved in EGFR ubiquitination and internalization.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target-Kategorie:
The synthetic peptide sequence used to generate the antibody AP8668c was selected from the Center region of human CBLB. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
